Risk factors of outcomes associated with disease progression in patients with Atrial Fibrillation and Heart Failure (HF) who are receiving a direct oral anticoagulant (rivaroxaban) (FARAONIC)
Evaluation of the risk factors associated with Heart Failure (HF) worsening (measured by hospitalizations and emergency visits because of HF exacerbations) in Spanish patients with Atrial Fibrilation and HF treated with rivaroxaban.
- Adult males and females aged 18 years or older. - Patients with a diagnosis of nonvalvular Atrial Fibrilation (AF). - Patients with a diagnosis of chronic Heart Failure, New York Heart Association (NYHA) class I-IV HF with preserved Ejection Fraction (HFpEF), HF with reduced EF (HFrEF) or HF with mid-range EF (HFmrEF). - Patients receiving antithrombotic treatment because of AF, with rivaroxaban since at least 4 months before entering the study. - Patients who have been given appropriate information about the study objectives and procedures and with the mental and physical capacity to give their informed consent to participate in the study.
- Patients participating in a research program which involves some intervention beyond clinical practice. - Patients who started rivaroxaban after the start of the inclusion period. - Patients with significate mitral stenosis or other heart valvular diseases that requires or have needed specific treatment (prosthesis or valvuloplasty). - Patients with severe cognitive impairment.
Many Locations, Spain
E-mail: [email protected]
Phone: (+) 1-888-8422937
Risk factors of outcomes associated with disease progression in patients with Atrial Fibrillation and Heart Failure (HF) who are receiving a direct oral anticoagulant (rivaroxaban)